Maze Therapeutics’ (MAZE) Buy Rating Reiterated at BTIG Research

by · The Markets Daily

BTIG Research reaffirmed their buy rating on shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) in a report published on Tuesday morning,Benzinga reports. BTIG Research currently has a $46.00 price objective on the stock.

Several other equities research analysts have also issued reports on MAZE. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Maze Therapeutics presently has a consensus rating of “Buy” and an average target price of $63.40.

Get Our Latest Stock Report on Maze Therapeutics

Maze Therapeutics Stock Down 6.7%

Shares of Maze Therapeutics stock opened at $26.21 on Tuesday. The business has a 50-day moving average price of $27.16 and a 200 day moving average price of $29.04. Maze Therapeutics has a fifty-two week low of $21.95 and a fifty-two week high of $53.65. The firm has a market cap of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts’ consensus estimates of ($0.76). On average, sell-side analysts forecast that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,142 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the transaction, the chief marketing officer directly owned 16,142 shares of the company’s stock, valued at $445,680.62. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00. Following the completion of the transaction, the insider owned 26,250 shares of the company’s stock, valued at approximately $717,675. This trade represents a 22.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 191,459 shares of company stock worth $5,263,539. Insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its holdings in shares of Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after buying an additional 1,383 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Maze Therapeutics during the second quarter worth about $48,000. Quantbot Technologies LP acquired a new position in Maze Therapeutics during the second quarter worth about $80,000. Caitong International Asset Management Co. Ltd bought a new stake in Maze Therapeutics in the fourth quarter worth about $145,000. Finally, IFP Advisors Inc bought a new stake in Maze Therapeutics in the fourth quarter worth about $146,000.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

  • Positive Sentiment: New buy ratings support the investment case. Citigroup and BTIG both initiated coverage with Buy ratings and $50 price targets, implying substantial upside from the recent $26.21 reference price. Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target BTIG Initiates Maze Therapeutics at Buy With $50 Price Target
  • Positive Sentiment: Existing analysts remain bullish. HC Wainwright reaffirmed its Buy rating and $110 target, while Wedbush maintained an Outperform rating with a $48 target. These targets reflect analysts’ confidence in Maze’s pipeline, although they also indicate considerable execution risk for a clinical-stage biotechnology company. HC Wainwright Reaffirms Maze Therapeutics Buy Rating
  • Positive Sentiment: Recent coverage has generated investor interest. Shares rose 2.9% after CIBC initiated coverage, indicating that new brokerage coverage can provide short-term support for MAZE. Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage
  • Neutral Sentiment: Reported short interest is zero shares. The September 24 report lists no short positions and a 0.0-day short-interest ratio. This removes evidence of meaningful short-selling pressure or squeeze potential, though the figure may reflect a reporting or data anomaly rather than a fundamental change.
  • Neutral Sentiment: Sector news is supportive but indirect. Strong results for a rival kidney-drug developer may reinforce interest in the biotechnology and renal-disease markets, but the development does not directly change Maze’s financial results or clinical outlook. Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.

Further Reading